CYDY (CytoDyn) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


CYDY CytoDyn Inc CYDY
28 GF Score
Price $0.23
! 1 Warning Sign
View Full Analysis

What is CytoDyn Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

CytoDyn's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CYDY vs ZURA, XFOR, LYEL: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, CytoDyn's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where CytoDyn's Margin of Safety % (DCF Earnings Based) falls into.


CYDY
28GF Score
CytoDyn Inc CYDY
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Business Description

Other Exchanges 296:Germany
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score

Get the complete analysis for CYDY

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price